Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$1,230 Mln
P/E Ratio
--
P/B Ratio
1.35
Industry P/E
--
Debt to Equity
0.67
ROE
-0.09 %
ROCE
-5.14 %
Div. Yield
0 %
Book Value
7.1
EPS
-0.62
CFO
$30.30 Mln
EBITDA
$122.24 Mln
Net Profit
$-233.72 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
NeoGenomics (NEO)
| -42.05 | -2.80 | -31.69 | -31.05 | -8.11 | -19.46 | 7.08 |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
NeoGenomics (NEO)
| 1.84 | 75.11 | -72.92 | -36.63 | 84.07 | 131.96 | 42.05 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 140.03 | 11,202.40 | 13.05 | 159.08 | |
| 103.35 | 10,408.27 | 23.02 | 24.54 | |
| 121.81 | 11,495.49 | 3.72 | 110.75 | |
| 174.80 | 11,397.43 | 10.39 | 17.71 |
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through two segments: Clinical Services and Advanced Diagnostics. The company offers testing services to hospitals,... academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida. Address: 9490 NeoGenomics Way, Fort Myers, FL, United States, 33912 Read more
CEO & Director
Mr. Christopher Michael Smith BSc
CEO & Director
Mr. Christopher Michael Smith BSc
Headquarters
Fort Myers, FL
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of NeoGenomics Inc (NEO) stood at $ 1,638 Mln as on 31-Dec-24
The share price of NeoGenomics Inc (NEO) is $9.55 (NASDAQ) as of 17-Apr-2025 16:00 EDT. NeoGenomics Inc (NEO) has given a return of -8.11% in the last 3 years.
NeoGenomics Inc (NEO) has a market capitalisation of $ 1,230 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of NeoGenomics Inc (NEO) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the NeoGenomics Inc (NEO) and enter the required number of quantities and click on buy to purchase the shares of NeoGenomics Inc (NEO).
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through two segments: Clinical Services and Advanced Diagnostics. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida. Address: 9490 NeoGenomics Way, Fort Myers, FL, United States, 33912
The CEO & director of Mr. Christopher Michael Smith BSc. is NeoGenomics Inc (NEO), and CFO & Sr. VP is Mr. Christopher Michael Smith BSc.
There is no promoter pledging in NeoGenomics Inc (NEO).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,137
|
|
|
1,132
|
|
|
1,132
|
|
|
1,037
|
| NeoGenomics Inc. (NEO) | Ratios |
|---|---|
|
Return on equity(%)
|
-8.54
|
|
Operating margin(%)
|
-11.21
|
|
Net Margin(%)
|
-11.92
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of NeoGenomics Inc (NEO) was $0 Mln.
$-0.01
(
